It used to be that Chinese drug development was largely about creating "me too" drugs for the local market. But over the past ...

although it was approved only in late 2023. Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet another powerful growth driver ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. Lilly ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound ... telehealth company improperly referenced Lilly's approved drugs and clinical trials on its website in order to ...

According to The New York Times, the most popular of the drugs are Wegovy, made by Novo Nordisk, and Zepbound, made by Eli Lilly ... weight loss by Medicare, but the FDA in early 2024 approved ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released clinical trial results for its oral ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...